1. Introduction {#s0005}
===============

There is a lack of consensus between guidelines regarding the most appropriate test for patients with stable coronary artery disease (CAD) [@b0005], [@b0010], [@b0015], [@b0020]. Studies such as the SCOT-heart and PROMISE trials have challenged the notion that functional testing was the optimal initial non-invasive test [@b0025], [@b0030], [@b0035]. These and other studies have led recent guideline changes suggesting that coronary computed tomography angiography (CCTA) be a first-line test [@b0040].

Although there is disagreement in patients with suspected CAD, there is consensus that functional imaging should be the first test in stable symptomatic patients with established CAD [@b0005], [@b0015], [@b0020]. It may be questioned, whether or not this recommendation is applicable to patients who have previously undergone coronary artery bypass surgery (CABG) because the interpretation of functional testing may have limitations. Functional imaging may not discern between native CAD or graft disease [@b0045], [@b0050], [@b0055], [@b0060]. Conversely, coronary CT angiography has been demonstrated to reliably assess graft patency and has prognostic value [@b0065], [@b0070], [@b0075], [@b0080], [@b0085]. CCTA also appears to be less expensive as an index test and cost effective in comparison to functional imaging [@b0090]. Whether cost effectiveness is maintained in patients with established CAD is unknown, should CCTA increase downstream testing it may counteract any initial potential savings of CCTA as the index test [@b0035]. Given the growing prevalence of CAD, downstream resource utilization and cost are likely to be an important factors in determining whether health service providers should adopt CCTA.

We therefore sought to determine the downstream resource utilization and its associated costs in CABG patients receiving CCTA or SPECT myocardial perfusion imaging (MPI) as the initial investigation.

2. Methods {#s0010}
==========

2.1. Study population {#s0015}
---------------------

Consecutive CABG patients who had undergone a clinical requested SPECT MPI or CCTA between January 2006 to July 2013 were retrospectively identified. This first scan was defined as the index investigation (index scan).

2.2. Index test selection {#s0020}
-------------------------

Selection of the index scan was left to the discretion of the referring clinician. Choice of a particular strategy over the other may have reflected patient symptom characteristics, physician perceptions and/or logistical issues. Both investigation strategies have been available locally for \>10 years. Both techniques have excellent clinical and academic standing within the service region [@b0070], [@b0095]. In order to improve comparability between the two groups and lessen the impact of selection bias to impact test selection two further analyses of the data were planned. Firstly, a propensity adjustment was made based upon differences in the baseline characteristics. Secondly, we performed an analysis which excluded patients who subsequently received redo-revascularization. This was performed for it might be argued that any downstream testing that lead to revascularization could not be considered to be an effect of the index test.

2.3. Downstream testing {#s0025}
-----------------------

The patient electronic medical record was reviewed to ascertain downstream cardiac investigations within six months of the index scan [@b0100]. Downstream testing (coronary angiography, SPECT, CCTA, positron emission tomography (PET) and/or stress echocardiography) was recorded. If multiple investigations were performed all tests were included. Revascularization with (percutaneous coronary intervention (PCI) or redo-CABG) were also captured. This study was approved by the local Research Ethics Board.

3. CCTA and SPECT image acquisition {#s0030}
===================================

3.1. Coronary CT angiography {#s0035}
----------------------------

CCTA image acquisition was performed using a single or dual-source 64-slice computed tomography scanners and reported as per SCCT (society of cardiovascular computed tomography) recommendations [@b0105].

3.2. Tc-99 SPECT MPI {#s0040}
--------------------

Tc-99m SPECT myocardial perfusion imaging was performed and reported as per ASNC (America Society of Nuclear Cardiology) recommendations [@b0110].

3.3. Cost assessment {#s0045}
--------------------

Calculations were made with reference to Medicare and Medicaid physician fee schedule and the payment rate for medical hospital outpatient prospective system [@b0095], [@b0115]. Revascularization procedures were included in the analysis of economic impact.

3.4. Statistical analysis {#s0050}
-------------------------

Continuous variables are presented as means and standard deviations and categorical variables as frequencies with percentages. Categorical variables were compared using Chi Square tests. Continuous variables were assessed using independent sample *t*-tests. Univariable analysis and multivariable analyses were performed using a propensity score adjusting for variables that were statistically different between groups (BMI, age, smoking status, presence of dyslipidemia, diabetes and the presence of symptoms). Data were analyzed using IBM SPSS 25 statistics for Windows (Armonk, NY: IBM Corp). Statistical significance was defined as p \< 0.05.

4. Results {#s0055}
==========

4.1. Baseline characteristics {#s0060}
-----------------------------

A total of 23,553 patients who underwent CCTA (6553) or SPECT (17,000) between 2010 and 2013 were screened. Of these 2754 CABG patients were identified and analysed (591 CCTA and 2163 SPECT). The SPECT cohort was older, had lower BMI and were less likely to smoke. The CCTA cohort had a higher prevalence of dyslipidemia and symptoms (chest pain, and dyspnea) ([Table 1](#t0005){ref-type="table"}).Table 1Patient characteristics.CharacteristicsCCTA index (n = 591)SPECT index (n = 2163)P ValuesAge (year) ± SD66.8 ± 9.268.8 ± 9.8P \< 0.001Male (n) %481 (81.4%)1725 (80.2%)P = 0.189BMI (kg/m^2^) ± SD29.3 ± 5.628.2 ± 5.1P \< 0.001Cardiac Risk FactorsHypertension (n) %405 (68.5%)1783 (82.4%)P \< 0.001Dyslipidemia (n) %550 (93.1%)1869 (86.4%)P \< 0.001Diabetes (n) %190 (32.1%)711 (32.9%)P = 0.370Current smoker (n) %70 (11.8%)257 (11.9%)P = 0.490Ex-Smoker (n) %337 (57%)1143 (52.8%)P = 0.035  SymptomsChest pain (n) %324 (54.8%)881 (40.7%)P \< 0.001Dyspnea (n) %358 (60.6%)1122 (51.9%)P \< 0.001

4.2. Downstream investigations {#s0065}
------------------------------

In total 425 patients (15.4%) underwent downstream testing. Downstream testing was significantly higher in CCTA patients (23.2%) than SPECT patients (13.3%) (p \< 0.001) ([Fig. 1](#f0005){ref-type="fig"}) ([Table 2](#t0010){ref-type="table"}). There was no interaction between the propensity score and modality (CCTA versus SPECT) (p = 0.979).Fig. 1Further investigations and associated costs for patients undergoing index testing with CCTA versus SPECT.Table 2Downstream diagnostic testing.CCTA index (n = 591)SPECT index (n = 2163)P valuesCCTA (n) %054 (2.5%)--SPECT (n) %17 (2.9%)0--PET (n) %17 (2.9%)27 (1.2%)P = 0.003Coronary angiogram (n) %112 (18.9%)217 (9.9%)P \< 0.001Stress echocardiogram (n) %1 (0.2%)13 (0.6%)P = 0.432Patients undergoing downstream tests (%)23.2%13.3%P \< 0.001Number of tests per patients (propensity adjusted mean- 95% CI)0.252 (0.223--0.298)0.143 (0.118--0.156)P \< 0.001

Propensity adjusted analysis included adjustment for baseline differences at index test and included BMI, age, smoking status, presence of dyslipidemia, diabetes and symptoms. The differences in downstream testing were unchanged after adjusting for propensity score (23.2% (95% CI: 20.3--26.1%) and 13.3% (95% CI: 11.8--14.8%), p \< 0.001)). A total of 33 patients (7.8%) required multiple downstream tests, there was no difference in the number of patient requiring multiple tests between CCTA versus SPECT cohorts (12 following CCTA and 21 in SPECT patients).

4.3. Invasive coronary angiography and revascularization rates {#s0070}
--------------------------------------------------------------

Invasive cardiac catheterization was more common after CCTA than SPECT (18.9% and 9.9%, respectively; p \< 0.001 ([Table 2](#t0010){ref-type="table"}).

Revascularization rates were greater in the CCTA than the SPECT cohort (71 (12.0%) versus 103 (4.7%) patients, respectively; p \< 0.001). Redo CABG rates were low in both groups (0.34% in the CCTA and 0.14% in the SPECT groups (p = 0.642)). PCI was more frequent when the initial investigation started with CCTA (68 (11.5%)) versus SPECT (101 (4.6%); p \< 0.001).

4.4. Additional testing in patients not proceeding to repeat revascularization {#s0075}
------------------------------------------------------------------------------

When patients who either underwent PCI or repeat CABG were excluded from the analysis there were 520 patients whose index test was a CCTA and 2060 patients whose index test was SPECT. The number of downstream tests was still 36% greater in the CCTA group in comparison to the SPECT cohort: the mean number of downstream tests per patient for CCTA index group was 0.131 ± 0.35 (68 tests) versus 0.096 ± 0.33 (SD) for SPECT (200 tests) p = 0.018.

4.5. Financial costs {#s0080}
--------------------

When index test costs were included with downstream test expenses, the CCTA cohort demonstrated cost savings in comparison with the SPECT first cohort (mean cost per patient in CCTA group \$764.66 ± 29.59 versus \$1396.72 ± 10.12 for SPECT, p \< 0.001 [Table 3](#t0015){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}). In contrast when only downstream costs were considered without the inclusion of the index test expense, the average costs were 2 fold greater in the CCTA first group in comparison to the SPECT group (\$366.79 ± 29.59 versus \$167.35 ± 10.12, respectively; p \< 0.001, [Table 3](#t0015){ref-type="table"}).Table 3Downstream costs.Cost itemsCCTA index (n = 591)SPECT index (n = 2163)P valuesCCTA (n) %0\$21484.98--SPECT (n) %\$20899.460--PET (n) %\$23384.18\$37139.58P = 0.005Coronary angiogram (n) %\$115601.92\$223978.72P \< 0.001Stress echocardiogram (n) %\$236.78\$3078.14P = 0.191Repeat revascularization\$56652.09\$76289.28P = 0.585Downstream Costs\$216774.73\$361970.70P \< 0.001Total Costs Including Index Test\$451915.60\$3021119.64P \< 0.001

Total costs for the downstream investigations using 2019 Medicare fee schedule [@b0115] were \$578745.10 ([Table 3](#t0015){ref-type="table"}). The majority of downstream costs were attributable to invasive coronary angiography which occurred at almost twice the frequency in the CCTA group as compared to the SPECT group. Increased costs were also seen as a result of the downstream functional perfusion testing in the CCTA group from PET and SPECT.

5. Discussion {#s0085}
=============

We performed a retrospective study of 2754 consecutive CABG patients who underwent non-invasive testing for established coronary artery disease. We determined that there are downstream resource utilization and cost consequences associated with the first-test strategy selected. Previous studies have considered downstream utilization and financial implications in patients with suspected coronary disease [@b0025], [@b0035], [@b0100], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140]. Our study adds to the existing literature by examining the CABG population and suggests that a CCTA strategy leads to increased downstream investigation, increased invasive testing, and increased revascularization but reduced costs in comparison to a SPECT first strategy.

5.1. Subsequent investigations {#s0090}
------------------------------

Downstream testing was performed in 15% of patients. This is similar to the frequency of further testing in patients without prior coronary revascularization [@b0025], [@b0145]. For patients undergoing further testing this was usually a single test (92% of those undergoing downstream testing had a single test) and the most commonly test was invasive coronary angiography (72% of further tests were ICA). The rates of ICA in our study were comparable to those seen in prior studies, however the differences in frequency of downstream ICA between the index investigative strategies were greater than those previously seen [@b0025], [@b0035], [@b0135], [@b0145].

Some of the differences in downstream ICA rates following index testing may be related to the follow up period in prior studies. Trials associated with short term follow up of 2 years or less have noted increases rates of ICA associated with CCTA as the first test versus usual care or functional testing [@b0025], [@b0035], [@b0135], [@b0145]. In contrast studies that have included a longer term follow up of more than 4 years the rates of ICA were similar between the two strategies [@b0030].

5.2. Repeat revascularization {#s0095}
-----------------------------

In the current investigation repeat revascularization rates were higher in the CCTA group than the SPECT group (12% versus 5% of CCTA versus SPECT respectively, p \< 0.001). In patients with suspected CAD, there are conflicting reports in the literature as to whether CCTA increases revascularization [@b0030], [@b0035], [@b0120]. In CABG patients it is possible that the presence of diffuse severe coronary disease seen at CCTA might have proactively influenced revascularization decisions toward PCI in contrast to normal or low risk SPECT findings.

5.3. Economic impact {#s0100}
--------------------

Index testing with CCTA in CABG patients almost doubled the per-patient costs of downstream tests from \$167.35 with SPECT to \$366.79 with CCTA (p \< 0.001) ([Table 3](#t0015){ref-type="table"}). Prior studies have indicated a neutral effect on downstream tests following CCTA versus usual care or functional testing [@b0145]. In addition cost savings with CCTA have been noted in other comparisons when the index test was included in the cost calculation [@b0140]. This was observed in the present study as a consequence of the expense of SPECT in comparison to CCTA. ([Table 3](#t0015){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}).

There are however more financial costs involved with downstream testing that have not been accounted for in these results such as, office visits, routine blood work or day case admission for ICA with attendant ward and catheterization laboratory care. These may have had an important bearing on the true financial cost of a downstream test.

A further factor in the economic analysis is the initial expenditure for procurement of the imaging camera. Modern SPECT cameras which are approximately \$400,000 to \$600,000 are much less expensive that current CT machines which are \$2--2.5 million for a 256 or 320 detector camera. Whether the addition cost of the equipment can be recouped over time will depend on the efficiency of camera use, and the longevity of the equipment's service life. Thus although there are additional downstream costs from performing an index CCTA in CABG patients in comparison to SPECT, once index test cost and equipment costs are considered, the additional costs maybe cost neutral/saving.

5.4. Limitations {#s0105}
----------------

This was a retrospective study of consecutive patients. Although a propensity score was used to adjust for potential confounding variables it is possible that selection bias variables not accounted for in the propensity score influenced the results. A prospectively randomized study of CCTA versus SPECT in this population would be useful to better control for such potential confounders. Clinical outcomes were not considered in the current study. Whether the increase in ICA and subsequent increased revascularization in the CCTA group improves prognosis will be important to determine in future investigations.

This was a single centre study and although performed at a central tertiary referral centre with the regional cardiac catheterization and coronary interventional suite it is possible that some cases underwent further functional or ICA procedures at other centres and these investigations were not captured.

5.5. Conclusions {#s0110}
----------------

In CABG patients, the choice of initial investigation for stable ischemic coronary artery disease has an important influence on downstream testing, subsequent revascularization and health care costs. Our findings heighten the controversy regarding first test strategy in CABG patients by demonstrating that any potential cost saving of CCTA must be weighed against the increase in downstream testing associated with this modality. Prospective data that included more extensive evaluation of costs and clinical outcome data will be required therefore before CCTA replaces functional imaging as the first line investigation in CABG patients.
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